# Hour 03 PSL Scores: 03:00-03:59

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## PSL Scores at End of Hour 03

| Robot Type | Dim A (Omniscient) | Dim B (Omnipresent) | Dim C (Omnipotent) | PSL | Delta | Band |
|-----------|-------------------|--------------------|--------------------|-----|-------|------|
| Surgical Robots | 7.2 | 5.8 | 7.5 | 6.8 | 0.0 | Advanced |
| Cobots | 7.0 | 6.5 | 6.2 | 6.6 | 0.0 | Advanced |
| RT Positioning | 7.5 | 6.0 | 6.9 | 6.8 | +0.1 | Advanced |
| Needle-Placement | 6.8 | 5.5 | 6.5 | 6.3 | 0.0 | Advanced |
| Social Companion | 5.5 | 7.2 | 4.0 | 5.6 | 0.0 | Intermediate |
| Humanoids | 5.8 | 6.0 | 5.2 | 5.7 | 0.0 | Intermediate |
| RT Motion-Tracking | 7.8 | 6.2 | 7.0 | 7.0 | 0.0 | Advanced |
| Imaging Assistant | 7.0 | 6.8 | 5.8 | 6.5 | 0.0 | Advanced |
| Steerable Needle | 7.2 | 5.2 | 7.0 | 6.5 | 0.0 | Advanced |
| Rehab Exoskeletons | 5.5 | 5.8 | 5.5 | 5.6 | 0.0 | Intermediate |

## Cumulative Site PSL: 63.5 (Advanced Site)

## Scoring Changes This Hour

### RT Positioning - Dim C (Omnipotent): 6.8 -> 6.9 (+0.1)

Justification: RTPOS-01 completed an early-morning SRS mask fitting and CT
simulation session for PAT-ODMND-0008 (brain metastases, 3 lesions). The
procedure demonstrated high-precision 6-DOF positioning (0.4 mm deviation),
97.3% mask conformity, and successful CT simulation with 1 mm slice
resolution. Additionally, the AI lesion detection model identified all 3
known metastases and flagged a 4 mm region of interest in the right frontal
lobe for radiologist review, demonstrating enhanced procedural capability
beyond standard positioning. The successful early-hours execution with no
complications supports a 0.1 increase in the omnipotent dimension.

### All Other Robot Types - No Change

- Surgical Robots: No procedures this hour. Scores unchanged.
- Cobots: COBOT-01 completed a routine biopsy for PAT-ODMND-0009 with
  Grade A sample quality and 0.3 mm trajectory accuracy. Performance
  consistent with existing scores; no change warranted.
- Needle-Placement: No activity. Scores unchanged.
- Social Companion: COMPN-03 continued passive pediatric monitoring. No new
  capability demonstrated. Scores unchanged.
- Humanoids: No activity. Scores unchanged.
- RT Motion-Tracking: No activity this hour. Scores unchanged.
- Imaging Assistant: No activity. Scores unchanged.
- Steerable Needle: No activity. Scores unchanged.
- Rehab Exoskeletons: No activity. Scores unchanged.

## Site PSL Trend

| Hour | Site PSL | Delta | Key Driver |
|------|----------|-------|-----------|
| 00 | 63.4 | - | Baseline |
| 01 | 63.4 | 0.0 | No active procedures |
| 02 | 63.4 | 0.0 | PAT-ODMND-0007 RT session (standard performance) |
| 03 | 63.5 | +0.1 | RT Positioning Dim C increase (successful SRS setup) |

## USL Comparison Note

The USL framework (Kawchak, 2026; DOI: 10.5281/zenodo.18778220) evaluates
robot technical interoperability. Key USL scores for reference:

| Robot Platform | USL Score | PSL Score (this sim) |
|---------------|-----------|---------------------|
| da Vinci dVRK | 7.1 | 6.8 (Surgical) |
| Franka Panda | 7.4 | 6.6 (Cobot) |
| Boston Dynamics Atlas | 5.8 | 5.7 (Humanoid) |

The RT Positioning robot platform (comparable to clinical linear accelerator
couch systems with 6-DOF capability) demonstrates strong correlation between
USL technical interoperability and PSL clinical omnipotence, particularly
when AI-assisted lesion detection augments the positioning workflow. The 0.1
increase in Dim C reflects the successful integration of AI inference into
the SRS planning pipeline, consistent with USL evaluation criteria for
platform-level AI capability.

PSL and USL measure different aspects: USL focuses on technical unification
readiness while PSL focuses on clinical trial performance (omniscience,
omnipresence, omnipotence). The correlation between USL and PSL is moderate,
as high technical interoperability does not automatically translate to high
clinical omniscience or omnipresence.

## Patient Journey Framework Reference

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) maps individual patient trajectories through
Physical AI trial stages. PAT-ODMND-0008's SRS positioning session
represents Stage 3 (treatment planning) where PSL omnipotent scoring
directly reflects the robot's ability to achieve sub-millimeter positioning
accuracy for stereotactic applications. PAT-ODMND-0009's biopsy represents
Stage 2 (diagnostic workup) where cobot PSL scores reflect tissue
acquisition precision and sample adequacy.
